The most common treatments for cancer are radiation and chemotherapy. However they have side effects and also damage healthy tissues. Moreover, their effectiveness is limited when the cancer has spread through out the body. Researchers at the Niels Bohr Institute are therefore working to develop a gentler treatment that 'tricks' the cancer cells, which would absorb a cytotoxin and therefore be destroyed, while healthy cells would remain unaffected.

Walter Reed Army Institute of Research (WRAIR) researchers recently published the results of testing a Plasmodium vivax malaria vaccine candidate in a human challenge model. A vaccine to prevent infection and disease caused by P. vivax is critical to reduce sickness and mortality from vivax malaria, a common cause of malaria among deployed service members.

A single monoclonal antibody isolated from a human survivor of Ebola virus disease (EVD) completely protected monkeys from lethal infection with the virus, according to research published in today's online edition of the journal Science. Importantly, the antibody, known as mAb114, was effective even when given five days after exposure to Ebola virus, suggesting that it could hold promise as a potential treatment for human cases of EVD.

Australian researchers have resolved a mystery about how a promising new class of anti-cancer drugs, called nutlins, work - paving the way for improving the future of cancer treatment. Nutlins, which are in early clinical trials for treating blood cancers, sparked interest worldwide for their ability to stop cancer growth by activating the body's natural cancer-suppressing

Less than 40% of the results of clinical trials conducted at leading academic medical centers were shared within two years of completion, Yale School of Medicine researchers report in a new study published in the current issue of the British Medical Journal.

Pioglitazone, a drug used for type 2 diabetes, may prevent recurrent stroke and heart attacks in people with insulin resistance but without diabetes. The results of the Insulin Resistance Intervention after Stroke (IRIS) trial, presented at the International Stroke Conference 2016 in Los Angeles and published in the New England Journal of Medicine, suggest a potential new method to prevent stroke and heart attack in high-risk patients who have already had one stroke or transient ischemic attack.

Researchers are getting closer to learning how to turn white fat cells into brown fat cells, in a process called "beiging," to bring down blood sugar levels and fight diabetes. The team, led by Joseph Baur, PhD, an assistant professor of Physiology in the Perelman School of Medicine at the University of Pennsylvania published their findings this month in the journal Diabetes.